Abstract:Ubiquitin-specific peptidase 7 (USP7) is a deubiquitinating enzyme that mediates the stability and activity of numerous proteins. At basal expression levels, USP7 stabilizes p53 protein, even in the presence of excess MDM2. However, its overexpression leads to the deubiquitination of MDM2 at a rate faster than p53, leading to p53 degradation and pro-tumorigenic roles. Consequently, it is an attractive target for anticancer drug discovery via the modulation of its allosteric site from which the protein is activated. In this study, molecular modeling techniques and cheminformatics approaches were employed to unravel the potential of eighty compounds to serve as its allosteric site modulators. The compounds were initially subjected to virtual screening. Subsequently, the binding free energies of the top four compounds with the highest binding affinities were calculated, and their drug-likeness, and pharmacokinetic and toxicity profiles were evaluated. Ultimately, the complexes of the protein and hit compounds were subjected to a 100 nanoseconds (ns) molecular dynamics simulation. The results of the study revealed eight compounds from the compound library with docking scores ranging from - 7.491 to -11.43 kcal/mol, compared to P217564, which exhibited a docking score of -5.671 kcal/mol. The top four compounds with the highest affinities possessed drug-like properties, and good pharmacokinetic and toxicity profiles, and their predicted inhibitory potentials showed they will be effective at minimal concentration. Also, molecular dynamics simulation confirmed the stability of the protein-ligand complexes. Conclusively, the compounds identified in this study are worthy of further evaluation for the development of allosteric site modulators of USP7.

Identification of small‐molecule binding sites of a ubiquitin‐conjugating enzyme‐UBE2T through fragment‐based screening

Fragment-Based Covalent Ligand Screening Enables Rapid Discovery of Inhibitors for the RBR E3 Ubiquitin Ligase HOIP

Covalent Fragment Screening and Optimization Identifies the Chloroacetohydrazide Scaffold as Inhibitors for Ubiquitin C-terminal Hydrolase L1

Cellular Validation of a Chemically Improved Inhibitor Identifies Monoubiquitination on OTUB2

A method to identify small molecule/protein pairs susceptible to protein ubiquitination

Structural and biophysical characterisation of ubiquitin variants that inhibit the ubiquitin conjugating enzyme Ube2d2

Structural and biophysical characterisation of ubiquitin variants that specifically inhibit the ubiquitin conjugating enzyme Ube2d2

Insights into the Allosteric Inhibition of the SUMO E2 Enzyme Ubc9.

A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment

Discovery of Novel USP8 Inhibitors Via Ubiquitin-Rho-110 Fluorometric Assay Based High Throughput Screening.

Design of linked-domain protein inhibitors of UBE2D as tools to study cellular ubiquitination

Development of a robust HTRF assay with USP7 full length protein expressed in E. coli prokaryotic system for the identification of USP7 inhibitors

Targeting UBE2C for Degradation by Bioprotacs Based on Bacterial E3 Ligase

Identification and characterization of UBA5 inhibitors

Cheminformatics-aided discovery of potential allosteric site modulators of ubiquitin-specific protease 7

Small molecule inhibitors reveal allosteric regulation of USP14 via steric blockade

Highly specific intracellular ubiquitination of a small molecule

Virtual Screening Inhibitors of Ubiquitin‐specific Protease 7 combining Pharmacophore Modeling and Molecular Docking

In silico screening and computational evaluation of novel promising USP14 inhibitors targeting the palm-thumb pocket

Ubiquitin-specific proximity labeling for the identification of E3 ligase substrates

Cell-Based Covalent-Capture Deubiquitinase Assay for Inhibitor Discovery